• Founded: 2013
  • Location: Waltham, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin3
  • Therapy area: Virus-associated hemorrhagic cystitis
  • Drug types: INF, URO
  • Lead product: Posoleucel
  • Product link:
  • Funding: $75M stock Jun 2023; $127M stock Jul 2022; $318M IPO Jul 2020

job board

Short description:

Allogeneic, Off-The-Shelf, Multi-Virus Specific T-Cell Immunotherapies

Drug notes:

Also Clin3 adenovirus, Clin3 multi-virus prevention, Clin1b/Clin2 kidney transplant BK virus, Clin0 organ transplant virus protection; ALVR106 Clin1b/Clin2 multiple viral infections, Clin0 multiple viral infections; ALVR107 Clin0 HBV

Long description:

AlloVir focuses on designing treatments for viral infections in immunocompromised patients with limited or no conventional treatment options. Their platform utilizes virus-specific T cells (VSTs) from healthy donors to confer immunity to patients with T cell deficiencies. AlloVir products are available off the shelf, with 11 potentially devastating viruses currently targeted for treatment with VST technology. AlloVir creates VSTs by identifying viral antigens that produce robust T cell responses. Donors are screened and PBMCs are harvested and stimulated with peptide libraries targeting viral antigens. Promising candidates are selected and expanded while ensuring polyclonal populations. These virus-specific T cells are then cryopreserved and available off the shelf.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy